	perpetuity.	
All rights reserved	No reuse allowed	l without permission.
7 al lighto rooor root.		manoat pormiooion.

1	The role of cytomegalovirus in prostate cancer incidence and mortality
2	
3	Johanna Classon <sup>1</sup> , Abigail Britten <sup>2</sup> , Kanar Alkass <sup>3</sup> , Henrik Druid <sup>3</sup> , Nicole Brenner <sup>4</sup> , Tim
4	Waterboer <sup>4</sup> , Nicholas J Wareham <sup>2</sup> , Effrossyni Gkrania-Klotsas <sup>2,5*</sup> and Jonas Frisén <sup>1*</sup>
5	
6	<sup>1</sup> Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm,
7	Sweden
8	<sup>2</sup> Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge,
9	UK
10	<sup>3</sup> Department of Oncology-Pathology, Karolinska Institutet, Sweden
11	<sup>4</sup> Infections and Cancer Epidemiology Division, Deutsches Krebsforschungszentrum,
12	DKFZ, Germany
13	<sup>5</sup> Department of Medicine, Cambridge Biomedical Research Centre, Cambridge, UK
14	* Joint last author
15	
16	Address correspondence to Jonas Frisén, Jonas.frisen@ki.se and Effrossyni Gkrania-
17	Klotsas, egkraniaklotsas@nhs.net
18	
19	Keywords: Epidemiology; Cytomegalovirus; Prostate cancer incidence; prostate
20	cancer mortality
21	
22	Word count text: 5346
23	Word count abstract: 260
24	
25	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 26 ABSTRACT

27 Prostate cancer is one of the most common cancers in men with over 350 000 prostate cancer deaths reported worldwide every year. Current risk stratification models are 28 29 insufficient to predict prostate cancer and prostate cancer death. New biomarkers are needed to identify those at increased risk of lethal prostate cancer. Cytomegalovirus 30 31 (CMV) infection is common in the healthy prostate epithelium and promotes cell proliferation and viability in prostate cancer. Analyzing matched serum and tissue 32 samples from post-mortem donors (n=41) and prostate cancer patients (n=40), we 33 34 report that CMV seropositivity predicts high CMV abundance in prostate tissue. We 35 studied if CMV seropositive men had increased prostate cancer incidence and cancer 36 mortality in the European Prospective Investigation of Cancer (EPIC)-Norfolk 37 population-based cohort study. CMV IgG serostatus was determined between 1993 38 and 2000 in 7,655 men aged 40-81 years, of which 57% were CMV seropositive. Study participants were followed for 18±6.0 years (mean±SD). We used Cox proportional 39 40 hazard models, adjusted for age and potential confounders to estimate hazard ratios 41 (HR) with 95% confidence intervals (CI). CMV serostatus was not associated with 42 prostate cancer incidence (adjusted HR 1.03, 95% CI 0.89-1.19, p=0.687, 138,652 43 person-years). However, among prostate cancer patients, CMV seropositivity was 44 associated with increased risk of prostate cancer-associated mortality (adjusted HR 45 2.26, CI 95% 1.02-4.99, p=0.044, 4639 person-years), with 25% of seropositive and 18% of seronegative prostate cancer patients dying from their disease during follow 46 47 up. These results show that CMV seropositivity is associated with increased risk of prostate cancer death and suggest that CMV infection may contribute to prostate 48 49 cancer lethality.

- 50
- 51
- 52
- 53
- 54
- 55

- 57
- 58 59

### 60 INTRODUCTION

Prostate cancer is one of the most common cancers in men with over 350 000 prostate 61 cancer deaths reported worldwide every year<sup>1</sup>. Whereas many prostate tumors are 62 indolent, others can develop to metastatic disease, for which there is no cure. Few 63 environmental factors have been linked to prostate cancer development, but the 64 heritability of prostate cancer is  $57\%^2$ , with more than 250 germline single nucleotide 65 variants found to be associated with cancer incidence to date<sup>3</sup>. In contrast, only few 66 germline events have been identified as risk factors for prostate cancer mortality, 67 68 including carrying rare mutations in the gene BRCA2<sup>4</sup>, and potentially modifiable 69 environmental factors may play a larger role in cancer progression. A probable 70 relationship exists between smoking, obesity and advanced disease and risk for cancer progression, while physical activity might reduce this risk<sup>5</sup>. To date, tools that predict 71 72 who will develop lethal prostate cancer are insufficient. For example, the commonly 73 used Cancer of the Prostate Risk Assessment (CAPRA) score, which incorporates 74 tumor features, s-PSA and age at diagnosis of localized prostate cancer, moderately 75 predicts cancer-specific mortality (c-index 0.8)<sup>6</sup>. New biomarkers are essential to 76 identify those at risk of lethal prostate cancer.

77

Cytomegalovirus (CMV) is a human herpesvirus that establishes chronic infection and 78 79 globally 83% are seropositive to CMV<sup>7</sup>. However, seroprevalence differs markedly 80 around the world, with western countries having much lower rates than countries in 81 Africa and Asia<sup>7</sup>. CMV infection is present in a large fraction of normal prostate glands. prostate tumors and bone metastases<sup>8,9</sup>. In a case-control study, CMV serostatus was 82 not associated with prostate cancer incidence, suggesting that CMV does not cause 83 prostate cancer<sup>10</sup>. CMV seropositivity is, however, associated with increased all-cause 84 85 mortality<sup>11,12</sup>. In the US NHANES III cohort, CMV seropositive men had increased cancer mortality<sup>13</sup>, but it is unknown if CMV serostatus is specifically associated with 86 87 prostate cancer mortality. We recently reported that local CMV T-cell immunity in the prostate is associated with disease recurrence after radical prostatectomy in carriers 88 of the common allele HLA-A\*02-01<sup>14</sup>. Moreover, experimental CMV inhibition in 89 90 models of prostate cancer can induce growth arrest and programmed cell death<sup>9</sup>.

91

CMV seropositivity likely underestimates the infected proportion of the population 92 93 because CMV DNA is often detected along with low abundance of CMV responsive B-

and/or T-cells in seronegative individuals<sup>15-26</sup>. These findings suggest that individuals are infected but have failed to mount a detectable antibody response. In cells of the hematopoietic lineage, CMV is more abundant in CMV seropositive persons, although CMV often is present but at lower levels in individuals without an antibody response<sup>27</sup>-<sup>29</sup>. Large interindividual variation exists in abundance of CMV infected epithelial cells in the prostate, ranging from 0-100%<sup>9</sup>, raising the question whether CMV serostatus could also be a marker of CMV abundance in the prostate. Here we found that CMV was more abundant in benign prostates and prostate tumors in CMV seropositive compared to CMV seronegative men, demonstrating that CMV seropositivity serves as a marker for widespread CMV infection of the prostate. When we analyzed the large European Prospective Investigation of Cancer (EPIC)-Norfolk population-based cohort study, CMV serostatus was not associated with prostate cancer incidence. However, CMV seropositivity was associated with increased prostate cancer mortality in patients diagnosed with prostate cancer. 

### 128 **METHODS**

### 129 **Ethics Statement**

Ethical permission for study of human samples was granted by the regional ethics committee of Sweden (2010/313-31/3). Prostate tissue and blood samples were collected from post-mortem donors between 2015 and 2020 through KI Donatum, Karolinska Institutet, Stockholm, Sweden, as described in<sup>14</sup> and<sup>9</sup>; post-mortem cohort.

De-identified prostate cancer FFPE tissue from prostatectomy specimens with
matched plasma (age span 50-68 years of age) was received from the Prostate Cancer
Biorepository Network (PCBN) biobank; prostatectomy cohort. Ethical permission for
biobank tissue collection was obtained from the local institutional review board at
Memorial Sloan Kettering Cancer Center, New York, USA (Protocol #15-025).

140

The European Prospective Investigation of Cancer (EPIC)-Norfolk study was approved by the Norwich Local Research Ethics Committee (previously known as Norwich District Ethics Committee) (REC ref: 98CN01; 05/Q0101/191) and Waveney NHS Research Governance Committee (2005EC07L). All participants gave their informed written consent before entering the study. Permission to analyze EPIC-Norfolk data by Swedish researchers was granted by the Swedish Ethical Review Authority, ethical permit number 2021-00457 and its amendment 2022-00965-02.

148

## 149 Analyses of CMV immunity in post-mortem and prostatectomy cohorts

150 We analyzed anti-CMV IgG titers in serum of post-mortem donors and in plasma of prostatectomy prostate cancer patients from PCBN using CMV IgG, CMIA assav 151 152 (Architect, Abbott, Chicago, Illinois, USA). The cut-off value for a positive assay was 153 6.0 arbitrary units (AU) and measured values up to 250. Samples that had titers of 250 154 or higher were labeled  $\geq$  250. Four post-mortem donors were analyzed by CMV IgG chemiluminescence immunoassay on the LIAISON®XL Analyzer. Here >14 was 155 156 considered positive (U/ml). We determined CMV IgG avidity using human anti-157 cytomegalovirus IgG ELISA Kit (ab108639, Abcam, Cambridge, UK) using low and 158 high avidity controls (CMV IgG and IgG avidity EIA, DEIA465, Creative Diagnostics, 159 New York, New York, USA). After sample incubation, wells were incubated with either 160 1X wash buffer or 6M urea in 1X wash buffer for 10 minutes. We calculated an index

of CMV IgG avidity between non-urea and urea treated wells. High avidity: 0,80-1,00;
Intermediate avidity: 0,65-0,79; Low avidity: <0,65.</li>

163

Virscan data with Virscores were extracted from<sup>14</sup>, in which the analysis was further 164 165 described, and compared with epithelial CMV-pp71 abundance as analyzed in <sup>9</sup>. In 166 brief. VirScan is a method to analyze antiviral IgG antibodies by using genetically 167 engineered bacteriophages that display short peptides spanning viral genomes<sup>30</sup>. 168 Prostate protein lysates were incubated with bacteriophages, IgG-bacteriophage 169 complexes were captured using magnetic beads and sequenced. CMV VirScores, 170 reflecting the number of CMV epitopes recognized by IgG antibodies in a sample, were 171 determined as in<sup>31</sup>. The VirScan method is prone to false positive hits, and CMV 172 VirScore of above five was here considered as CMV VirScore high.

173

# Analyses of prostate tissues from post-mortem donors and prostate cancerpatients

Tissues were processed and analyzed as described in <sup>9</sup>. Immunohistochemistry
protocols and imaging are described in <sup>9</sup>. This antibody was used: Cytomegalovirus
pp71 (goat, 1:200, clone vC-20, sc-33323, polyclonal, Santa Cruz Biotechnology).

179

180 Histological evaluation of prostate cancer and inflammation was assessed in H&E 181 stained FFPE prostate slides by a trained pathologist. Cells with lymphocyte 182 morphology in large and small clusters or spread out in the stroma were classified as 183 chronic inflammation. Acute inflammation with neutrophile infiltration was detected in 184 three prostates in which chronic inflammation was also detected. An incidental prostate 185 cancer (Gleason score 3+3) was detected in a CMV seronegative subject. A suspected 186 incidental prostate cancer was detected in a CMV seropositive subject but was difficult 187 to further assess due to post-mortal effects on the tissue. Two other individuals had 188 been treated for prostate cancer with local radiation and chemotherapy respectively. 189 Medical history was obtained from medical journals, next of kin, police reports and 190 patient registry, all in accordance with ethical permit 2010/313-31/3.

191

In prostatectomy samples from PCBN (prostate cancer patients aged 50-68y),
 Gleason score and pathological T-stage were recorded by pathologists associated with

7

PCBN. Gleason grade groups 1-5 were derived from Gleason scores according to theInternational Society of Urological Pathology.

196

### 197 Statistical analyses of post-mortem and prostatectomy cohorts

198 All statistical analyses and plots for the cohort with post-mortem donors and the 199 prostatectomy cohort were made in GraphPad prism 8.0 (GraphPad Software, San 200 Diego, California, USA). Two-sided unpaired t-tests were performed on numerical 201 continuous data with normal distribution. Groups with non-normal numerical 202 continuous data was analyzed with Mann-Whitney test. Correlation analyses were 203 performed with Pearson correlation analysis or Spearman correlation analysis when 204 appropriate. Proportions between two groups was analyzed with Fisher's exact test. 205 Non-normal distributed data with more than two groups was compared with Kruskal-206 Wallis multiple comparisons. Receiver operator characteristic (ROC) curves were 207 constructed and Area under the curve (AUC) calculated using % CMV-pp71 epithelial 208 abundance in CMV IgG- and CMV IgG+ donors or patients. Patients with CMV IgG 209 titers of  $\geq$  250 were all treated as having CMV IgG titer 250 in analyses.

210

### 211 EPIC-Norfolk cohort characteristics

The EPIC-Norfolk study is a prospective population-based cohort in the UK that recruited study participants between 1993 and 1997, aged 40-79 years at time of inclusion. The cohort, with details on methods of data collection and follow up, has previously been described<sup>12,32</sup>. Participants subjected to CMV serology testing were randomly selected from the EPIC-Norfolk cohort<sup>12,33</sup>. End of follow-up was 2018 March 31<sup>st</sup>.

218

## 219 Serum CMV IgG measurements in the EPIC-Norfolk cohort

220 In total, 7655 male study participants underwent CMV serology testing. CMV IgG serostatus was determined in serum from blood drawn on 1<sup>st</sup> health check (1993-1998, 221 n=5894) and/or 2<sup>nd</sup> health check (1998-2000, n=3846). In blood collected at 1<sup>st</sup> health 222 223 check, serum CMV IgG measurements were performed using an indirect 224 chemiluminescence immunoassay (Liaison, Diasorin, Saluggia, Italy). The CMV serology assessment procedure in blood samples collected at 1<sup>st</sup> health check has 225 previously been described in detail<sup>12</sup>. In blood collected at 2<sup>nd</sup> health check, CMV 226 227 serostatus was determined by assaying CMV epitopes, performed at the German

8

Cancer Research Center, Heidelberg, Germany, as previously described<sup>34</sup>. In
 summary, antibodies against two or more antigens (CMV pp28, CMV pp52, CMV pp65,
 CMV pp150), with assay values above cut off values determined a priori, were
 considered as CMV seropositive.

232

# 233 Variables collected at baseline in EPIC-Norfolk

Self-reported information on smoking, diabetes mellitus, alcohol usage, Townsend
index<sup>35</sup>, education level, Body Mass Index, Waist-hip ratio, social class, ethnic origin,
and marital status were collected at 1<sup>st</sup> health check (1993-1998).

237

# 238 **Prostate cancer variables and endpoints in EPIC-Norfolk**

Information on prevalent (present at determination of CMV serostatus) and incident 239 240 prostate cancer (diagnosed after determination of CMV serostatus) was ascertained 241 using ICD-10 code C61 in the UK Cancer Registry until 2016 March 31<sup>st</sup>, the latest 242 available UK Cancer Registry data. Information on prostate cancer diagnosis, 243 documented using ICD-10 codes 185, C61, was extracted from hospital admission and 244 mortality data until 2018 March 31<sup>st</sup>. Hospital admissions data include all ICD codes 245 recorded at admissions to hospital, independent of the reason. Prostate cancer diagnosis at hospital admissions is registered as date of admission and not backdated 246 247 to the date the patient received his diagnosis. Death certificates were obtained for all 248 participants who died before end of follow up at 2018 March 31<sup>st</sup>. Prostate cancer as 249 underlying cause of death (185, C61) was used as the endpoint prostate cancer 250 mortality.

251

252 Information on prostate cancer stage at diagnosis was documented in the UK cancer 253 register for 284 prostate cancer patients, with 278 being incident prostate cancer 254 cases, divided into general American Joint Committee on Cancer (AJCC) stage groups 255 using TNM classifications. Patients were divided into categories 1-4 and 6, of which 256 category 6 had insufficient information to produce a valid stage. Categories 1-4 were 257 used, which correspond to cancer stage I-IV. Cancer was classified into localized 258 prostate cancer (stage I-II; local growth; T2 or lower, N0, M0) and advanced prostate 259 cancer (stage III-IV; tumor has invaded surrounding tissue and/or presence of lymph 260 node metastases and/or presence of distant metastases; T3 or higher, or N1 or M1).

9

### 262 Statistical analyses of EPIC-Norfolk

263 All analyses of EPIC-Norfolk data were executed in STATA SE 17 (Stata-Corp, College Station, Texas). All data available was included as specified below. No power 264 265 calculations were conducted prior to this study. All tests of statistical significance were 266 two-sided. P-value below 0.05 was considered statistically significant.

267

268 Characteristics for variables were summarized using mean and standard deviation 269 (SD) for continuous variables and percentages for binary variables. Townsend index 270 was used as a continuous variable, as was alcohol consumption in units per week. 271 Age-adjusted linear regression analyses were performed to compare these variables 272 between CMV seronegative and CMV seropositive males and prostate cancer 273 patients. Binary variables: Prevalent Diabetes Mellitus (0/1), Ever smokers (0/1), Social 274 class: employment and above (0/1), Education; A level and above (0/1; A level 275 corresponds to 12 years of school education in the UK), Marital status; married or not 276 married (0/1), Body Mass Index ( $\geq$  30 or < 30 kg/m<sup>2</sup>), Waist-Hip ratio ( $\geq$  0.90 or < 0.90; 277 according to WHO definitions of high risk Waist-Hip ratio), Ethnic origin Caucasian or 278 non-Caucasian (black Caribbean, black other, Indian, Pakistani, Chinese, Other). 279 Binary variables were compared between CMV seronegative and CMV seropositive 280 males using logistic regression adjusted for age. Data completeness was 97% or 281 higher for all individual variables.

282

In time-to-event models, time from serostatus was determined using data from 1<sup>st</sup> 283 284 health check or 2<sup>nd</sup> health check. These two health checks were two years apart. If a 285 participant was CMV seronegative on both 1<sup>st</sup> health check and 2<sup>nd</sup> health check, time 286 from CMV serostatus is determined as time from 1<sup>st</sup> health check. If a participant was seronegative on 1<sup>st</sup> health check and seropositive on 2<sup>nd</sup> health check, time from CMV 287 serostatus is determined as time from 2<sup>nd</sup> health check. If a participant was seropositive 288 on 1<sup>st</sup> health check and seronegative on 2<sup>nd</sup> health check, time from CMV serostatus 289 is determined as time from 1<sup>st</sup> health check (this pattern was observed for a rare 290 291 number of study participants with CMV serostatus data from both 1<sup>st</sup> health check and 2<sup>nd</sup> health check; 47/1160: 4.1%). CMV IgG titers are stable over time<sup>36</sup>. As described 292 in Table S2, CMV seroprevalence in matched age groups was lower in 2<sup>nd</sup> health check 293 294 compared to 1<sup>st</sup> health check, implying that the sensitivity is lower, causing false 295 negative CMV seronegative samples to occur.

10

296

Time to prostate cancer was determined as time to first prostate cancer registration, either in the prostate cancer registry or by registration upon hospital admission. Time from prostate cancer diagnosis to prostate cancer mortality was determined as time from first prostate cancer registration (Figure 2). Censored subjects in time-to-event analyses were either censored due to death from other causes than prostate cancer or were censored at end of study (2018, March 31<sup>st</sup>).

303

304 In time-to-event models, only patients with no missing data were analyzed. Time to 305 event analyses were performed in study participants and patient with  $\geq$  two years follow 306 up excluding patients with prevalent prostate cancer. Time-to-event models were 307 performed for all men from time of known serostatus to first prostate cancer registration 308 or prostate cancer death and for prostate cancer patients from time of first registered 309 prostate cancer diagnosis to prostate cancer death (Figure 2). Three time-to-event 310 models were examined: 1) Unadjusted; 2) Adjusted for Age; 3) adjusted for Age, 311 Smoking, Diabetes Mellitus, Body Mass Index, Waist-Hip Ratio, Education level and 312 Townsend index. Assumptions of proportional hazards were examined by Schoenfeld 313 residual statistical measures for each variable. If the assumption of proportional 314 hazards was not fully justified for a variable, it was converted into a time-dependent 315 variable in Cox proportional hazard models.

- 316
- 317318
- 319
- 517
- 320
- 321322
- 323
- 324
- 325
- 326
- 327
- 328
- 329
  - 29

11

### 330 RESULTS

### 331 Relationship between CMV serostatus and CMV infection in the prostate

332 We recently reported that chronic CMV infection is common in the prostate using 333 immunoblot, immunohistochemistry (IHC), guantitative PCR and in situ hybridization 334 with the proportion of CMV infected cells in the prostate epithelium ranging from 0-335 100%<sup>9</sup>. To assess the relationship between CMV infection in the prostate and CMV 336 serostatus, we measured CMV IgG in serum of 41 post-mortem donors aged 19-89 in 337 whom we quantified CMV abundance in the prostate.

338

339 In CMV seropositive post-mortem donors (24/41, 59%), the proportion of the prostate 340 epithelial cells that was infected by CMV ranged from 2% to 100% with a mean of 58%, as assessed by the detection of the CMV protein pp71 by IHC (n=24, Figure 1A). It is 341 342 well established that CMV infected individuals often are seronegative<sup>15-26</sup>, and 343 prostates from the 17 CMV seronegative post-mortem donors were all CMV IHC 344 positive, but epithelial abundance of CMV was significantly lower than in CMV 345 seropositive post-mortem donors with a mean of 28% (p<0.0001, Figure 1A).

346

347 We also found a positive association between a high CMV IgG VirScore in prostate 348 tissue<sup>14,30</sup>, reflecting presence and diversity of CMV IgG antibodies, with CMV-pp71 epithelial abundance (n=15, p=0.003) (Figure 1B), further supporting an association 349 350 between CMV immunity and epithelial CMV infection. Prostates of CMV seropositive 351 donors did not have higher prevalence of inflammatory infiltrates with lymphocytes than 352 in CMV seronegative donors (Figure S1A). Neither was presence of inflammatory 353 infiltrates associated with CMV abundance in CMV seronegative nor CMV seropositive 354 donors (Figure S1B), ruling out general chronic inflammation as a mediator.

355

A more pronounced association between CMV serostatus and prostate CMV 356 357 abundance, determined with CMV-pp71 IHC, was observed in prostate cancer patients 358 who underwent prostatectomy (Prostatectomy cohort). First, 3/10 of prostatectomy 359 samples from CMV seronegative prostate cancer patients had CMV negative tumors 360 and CMV negative benign epithelium (Figure 1C). Second, CMV was commonly found 361 throughout the whole tumor in CMV seropositive patients (Figure 1C, n=10) whereas CMV was less abundant in the tumor in CMV seronegative patients (IgG+ vs IgG-, 362 363 >90% CMV<sup>+</sup>: p=0.023, n=10 per group, Figure 1C). The median CMV tumor

abundance was 99% in CMV seropositive patients (n=10) and 47% in CMV
seronegative patients (n=10) (p=0.016; Figure 1C).

366

367 With higher age, titers of anti-CMV IgG antibodies increase, perhaps due to subclinical 368 reactivation events<sup>28,37</sup>. Prostate CMV abundance is positively correlated with age<sup>9</sup>, 369 but when we analyzed CMV seronegative and CMV seropositive donors separately, CMV abundance only increased with age in CMV seronegative donors (CMV IgG-: 370 r=0.72, p=0.001; CMV IgG<sup>+</sup>: r=0.25, p=0.24; Figure S2A). Furthermore, serum CMV 371 372 IgG titer did not correlate with prostate CMV abundance in CMV seropositive donors 373 (r=0.03, p=0.90, Figure S2B) nor CMV abundance in prostate tumors in CMV 374 seropositive prostate cancer patients (r=0.28, p=0.44, Figure S2C). High avidity of 375 serum CMV lgG antibodies did not further discriminate CMV abundance (Figure S2D). 376 In conclusion, measures of systemic CMV humoral immunity guality (IgG avidity) and 377 quantity (IgG titer) could not be used to discriminate CMV abundance.

378

We asked how well CMV serostatus distinguished abundance of CMV in prostate epithelium. Receiver operator characteristic (ROC) analyses showed that CMV seropositivity identifies prostates with higher CMV abundance in post-mortem donors (Area under the curve (AUC): 0.85 (CI 95% 0.73-0.97), p=0.0002) (Figure 1D) and in primary prostate tumors (AUC: 0.81 (CI 95% 0.61-1.00), p=0.0191) (Figure 1E).

384

In summary, CMV seropositive men have higher abundance of CMV infected prostate
 cells than CMV seronegative men. Hence, CMV serostatus is a marker for CMV
 abundance in benign and malignant prostate tissue.

388

# 389 EPIC-Norfolk male CMV cohort characteristics

Next, we asked if CMV infection was associated with prostate cancer incidence or mortality. In order to do so, a large number of prostate specimens or blood samples are required. Since there is often CMV heterogeneity within a prostate, accurate assessment of CMV would entail analyzing large areas, which is difficult to do to in large scale. In contrast, CMV serostatus is analyzed with scalable assays in blood samples.

13

397 We used CMV serostatus to examine if CMV was associated with prostate cancer 398 incidence and mortality (Figure 2A-B). In EPIC-Norfolk, a total of 7655 male 399 participants aged 40-79 years at study recruitment in 1993-1997 were examined for CMV serostatus<sup>12,33</sup>. CMV serostatus was determined in serum from blood drawn 400 401 1993-1998 (n=5894) and/or 1998-2000 (n=3846) in males aged 40-81 years. The 402 study participants were followed for 18±6.0 years (mean±SD) from blood draw until the end of follow up due to death or end-of-study. Of the study participants, 57% were 403 404 CMV seropositive on at least one blood test (Table S1, Figure 2). As expected, since CMV seropositivity increases with age<sup>38</sup> (Table S2), CMV seronegative participants 405 406 were on average 2.9 years younger than CMV seropositive participants (58.6±9.1 vs 407 61.5±9.2 years; mean±SD) (Table S1). In age-adjusted analyses, CMV seropositive 408 men were more likely to be non-white, smokers, have high BMI, be married, have lower 409 level of education and had addresses in areas of material deprivation, as measured by 410 Townsend index score (Table S1).

411

412 Prostate cancer diagnoses were identified through the UK cancer registry (n=759) 413 and/or by hospital admissions (n=693), identifying a total of 839 prostate cancer 414 patients (Figure S3). Most patients were diagnosed with prostate cancer after CMV 415 serostatus was defined (incident cases, n=783, 93% of all cases) and 219 died from 416 prostate cancer during the study period. Incident prostate cancers were registered 417 11.9±6.0 years after CMV serostatus analysis.

418

419 Twenty prostate cancer patients had their cancer diagnoses registered at the same 420 time as death from the disease, which is likely due to delayed registration of diagnosis. 421 In addition, 11/205 (5.4%) of patients with localized prostate cancer stage at diagnosis 422 in the Cancer Registry died within two years, further substantiating that this error 423 occurs, as the 2-year survival of localized prostate cancer is nearly 100%. To account 424 for this bias, all time to event analyses were performed in study participants and patient 425 with  $\geq$  two years follow up.

426

### 427 CMV serostatus and prostate cancer incidence

428 In total, 483 (61.7%) of the men diagnosed with prostate cancer during follow-up were 429 CMV IgG<sup>+</sup> at the time of blood draw. CMV seropositive men were on average 2.5 years

- 430 older (mean 76.1± SD 7.9) than CMV seronegative men (mean 73.6± SD 7.8) when

431 their incident prostate cancer diagnoses were registered. CMV seropositivity was not 432 associated with increased risk of prostate cancer incidence during follow up in Cox 433 proportional hazard models adjusted for age (HR 0.99, 95% CI 0.85-1.14, p=0.848) or 434 smoking, diabetes mellitus, body mass index, waist-hip ratio, education level and 435 Townsend index in addition to age (HR 1.03, 95% CI 0.89-1.19, p=0.687) (Table 1). 436 Estimated crude incidence rate ratios (IRR) did not show an association between CMV and prostate cancer incidence (IRR 1.14 95% CI 0.99-1.32, p=0.068, 138,652 person-437 438 years) (Table S3). In addition, prostate cancer patients aged 50-68 years who 439 underwent prostatectomy (prostatectomy cohort) were not largely CMV seropositive 440 (CMV IgG-: 19/40, CMV IgG+: 21/40, Figure S4A). In conclusion, we find no evidence 441 of a general association between CMV and prostate cancer incidence.

442

### 443 CMV and prostate cancer characteristics

444 We next asked if CMV serostatus is associated with known prognostic prostate cancer 445 features. CMV seropositivity was not more prevalent in patients with advanced 446 compared to localized prostate cancer in EPIC-Norfolk at time of diagnosis (n=278, 447 age-adjusted p=0.487, advanced prostate cancer CMV seronegative: 31% and CMV 448 seropositive: 27%; localized prostate cancer CMV seronegative: 69% and CMV 449 seropositive: 73%, Table S4). In the prostatectomy cohort (n=40), prostate cancer 450 patients had T-stage pT2 or pT3 tumors with varying Gleason scores. CMV 451 seropositivity was not associated with T-stage (p=0.205; Fisher's exact test; Figure 452 S4B) nor Gleason grade group (p=0.078; Fisher's exact test; Figure S4C). CMV 453 abundance in primary prostate tumors (n=20) was not significantly associated with 454 Gleason score (grade group) or T-stage (Figure S4D-E, prostatectomy cohort). In 455 summary, CMV serostatus was not associated with the known prostate cancer 456 prognostic risk factors advanced prostate cancer stage, Gleason score or T-stage at 457 diagnosis, but appears to be an independent parameter.

458

### 459 CMV serostatus and prostate cancer mortality

Examining all men in the EPIC-Norfolk cohort, an association between CMV serostatus
and prostate cancer mortality was not apparent (adjusted HR 1.24, CI 95% 0.92-1.67,
p=0.166, n=7375, Table 2) but an effect of CMV seropositivity on all-cause mortality
adjusted for age and potential confounders was found (adjusted HR 1.10, CI 95% 1.02-

1.18, p=0.019, n=7375, Table 2). Crude incidence rate ratios for all mortality analyses 464 465 are reported in supplemental Table 7.

466

467 We next examined if CMV serostatus was associated with all-cause and prostate 468 cancer mortality specifically among patients diagnosed with prostate cancer. Of 469 incident prostate cancer patients. CMV seronegative patients were followed for 7.9±4.3 470 years (mean±SD) and CMV seropositive patients were followed for 7.6±4.4 years 471 (mean±SD) after prostate cancer registration. CMV seropositive prostate cancer 472 patients did not display increased all-cause mortality compared to CMV seronegative 473 prostate cancer patients, as examined in Cox proportional hazard models adjusted for 474 age and other potential confounders (fully adjusted HR 1.17, CI 95% 0.92-1.50, 475 p=0.206, n=588, Table 2).

476

During follow up, 24.7% of CMV seropositive patients and 17.6% of CMV seronegative 477 prostate cancer patients died from their disease. CMV seropositivity was associated 478 479 with higher risk of prostate cancer mortality in unadjusted (HR 2.47, CI 95% 1.12-5.43, 480 p=0.024, n=597) and age-adjusted (HR 2.32, CI 95% 1.06-5.13, p=0.036, n=597) Cox 481 proportional hazard models. The association persisted after adjusting for the potential 482 confounders smoking, diabetes mellitus, body mass index, waist-hip ratio, education 483 level and Townsend index in addition to age (HR 2.26, CI 95% 1.02-4.99, p=0.044, 484 n=588) (Table 2).

485

486 We conclude that CMV seropositivity, which correlated with higher abundance of 487 CMV in prostate epithelial cells, was associated with increased cancer mortality in prostate cancer patients.

- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495
- 496
- 497

### 498 DISCUSSION

499 We report that CMV infection is more widespread in epithelial cells in the healthy 500 prostate and in prostate cancer in CMV seropositive compared to seronegative men, 501 establishing CMV serostatus as a marker for CMV abundance in the prostate. In a 502 large prospective cohort, CMV serostatus was not associated with prostate cancer 503 incidence, corroborating previous research that found no association between DNA 504 virus immunity and risk of prostate cancer<sup>10,39,40</sup>. These findings imply that CMV is not an important cause of primary prostate cancer. We, however, report a positive 505 506 association between CMV seropositivity and prostate cancer mortality in prostate 507 cancer patients, independent of potential confounders such as obesity, smoking and 508 low socioeconomic status.

509

510 Many men who were CMV seronegative still had CMV infected prostates. This is not surprising, as it is well established that CMV serostatus substantially underestimates 511 512 the proportion of individuals who are infected by CMV<sup>15-22</sup>. Thus, we are not exclusively 513 comparing groups of individuals who are CMV infected or not, but who are infected to 514 varying degrees. Importantly, this raises the possibility that CMV potentially also may 515 affect prostate cancer mortality in the CMV seronegative group, but to a lesser extent, 516 and that the increased mortality after prostate cancer diagnosis in seropositive prostate 517 cancer patients may underestimate the true effect of CMV. Interestingly, CMV IgG titer 518 in blood could not be used to distinguish prostates with highest CMV abundance. 519 Factors such as age at infection and CMV strain variability may be more important.

520

This study has several strengths, including long follow-up time and high data 521 522 completeness. Furthermore, no study participants were lost during follow up other than 523 due to death prior to study completion. This study also has limitations. Over 99% of 524 study participants were of Caucasian ethnicity, all living in the UK. It is therefore difficult 525 to generalize the study results to other populations such as African American men in 526 USA or men in east Asia, two groups that display increased risk of prostate cancer mortality and have high CMV seroprevalence<sup>1,7,38,41</sup>. Although excluding participants 527 528 with less than two years follow up potentially reduced effects of bias introduced by late 529 registration of prostate cancer diagnoses, this strategy may potentially exclude a small 530 fraction of prostate cancer patients diagnosed with *de novo* metastatic prostate cancer 531 with poor outcome.

17

532

533 CMV seropositivity may be a marker of an altered immune system or of a yet 534 unidentified confounder that could explain the observed associations. Additionally, 535 CMV seropositivity could perhaps select for an earlier death from non-cancer causes 536 and result in selective survival bias, as CMV seropositivity is associated with all-cause 537 mortality and particularly mortality from cardiovascular disease<sup>11,12</sup>. However, we expect that any possible bias by selective survival is small and would not account for 538 539 our observations. A main cause of death among prostate cancer patients is 540 cardiovascular disease, and may therefore be a competing risk of death, particularly 541 among CMV seropositive men<sup>42</sup>. An association between CMV serostatus and 542 prostate cancer mortality is not as evident when analyzing all men in our cohort from 543 age of CMV serology, which may relate to the lack of increased incidence and 544 competing hazards.

545

546 The proportion of prostate cancer patients in EPIC-Norfolk diagnosed via s-PSA testing 547 or by showing clinical signs is unknown but could impact study results. CMV 548 seronegative men may be more likely to enroll in s-PSA testing as they in general have 549 higher socioeconomic status than CMV seropositive men (Table S1), which could 550 increase the number of indolent prostate cancer cases in CMV seronegative men. 551 However, adjusting for education level, Townsend index and smoking, among other 552 factors, did not reduce the effect measure of CMV's association with prostate cancer 553 mortality (Table 2). Furthermore, the proportion of patients with advanced cancer 554 disease at diagnosis in EPIC-Norfolk was not dependent on CMV serostatus (Table 555 S3), which suggests that confounding due to different diagnostic intensity is 556 improbable. Rather, trends in EPIC-Norfolk and prostatectomy cohorts suggest that 557 CMV seronegative patients may perhaps be diagnosed with prostate cancer with higher T-stage and Gleason scores than CMV seropositive patients (Table S4, Figure 558 559 S4B-C). Previous research has shown that there is no association between CMV serostatus and Gleason score<sup>10</sup>. The limited information on prostate cancer features 560 561 and low patient number in our study impede further exploration.

562

563 CMV may drive prostate cancer progression and metastatic spread independent of cellular differentiation (represented by Gleason score) and local invasion (represented 564 565 by T-stage), perhaps through early seeding. This is in contrast to prostate cancer

18

associated bacteria that may be associated with Gleason score<sup>43</sup> and characteristics of advanced disease<sup>44,45</sup>. This could be due to direct and indirect effects of CMV, For example, CMV-directed T-cells can skew immune responses<sup>46</sup> and potentially be prometastatic. In prostate cancer models, CMV directly promotes cell viability and proliferation<sup>9</sup>, two crucial features of malignant cells that allow tumors to accumulate alterations, perhaps induced by CMV, that result in metastatic disease.

572

It will be important to validate the potential of CMV seropositivity as a risk factor for 573 574 prostate cancer mortality in clinical cohorts, to further examine associations with 575 clinical factors, including treatment modality, s-PSA and family history of prostate 576 cancer. The potential added value of a CMV based assay, such as CMV serology, in 577 prostate cancer prognosis models will be essential to define but was not possible to 578 determine in this study. CMV promotes androgen signaling in prostate cancer and can 579 modulate cellular processes that are associated with resistance to therapies for 580 advanced prostate cancer<sup>9</sup>. It will be important to define if CMV is a predictive marker for the efficiency of anti-androgen therapies. Drugs that target CMV resulted in 581 582 inhibited growth and induced cancer cell death in CMV infected prostate cancer 583 models<sup>9</sup>. CMV serostatus has the potential to guide treatment choices and direct 584 patient treatment in clinical trials of anti-viral therapies such as maribavir and 585 letermovir<sup>9</sup>, with the hope that these, or other CMV targeted drugs, will prolong survival 586 of prostate cancer patients.

- 587
- 588
- 589
- 590
- 591
- 592
- 593
- 594
- 595

- 597
- 598
- 599

### **ACKNOWLEDGEMENTS**

All authors contributed to the study conception, study design, analysis, and interpretation of data. J.C and J.F wrote the manuscript with input from all authors. We thank the MRC Epidemiology Unit for access to data in the EPIC-Norfolk cohort. We thank the Karolinska University Hospital Clinical Microbiology Laboratory where CMV serology assays were performed for post-mortem and prostatectomy cohorts. We thank Professor Hans-Olov Adami and Lars Björnebo for valuable input on the manuscript. J.F and E.GK had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

### 610 FUNDING


This study was supported by grants from the Swedish Research Council (D0761801). the Swedish Cancer Society (19 0452 Pj, 22 2358 Pj), the Swedish Foundation for Strategic Research (SB16-0014) and Knut och Alice Wallenbergs Stiftelse (2018.0063). The PCBN biobank is supported by the Department of Defense Prostate Cancer Research Program Award No W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062 Prostate Cancer Biorepository Network. J.C was supported by the Clinical Scientist Training Program at Karolinska Institutet. E.GK was supported by the NIHR Cambridge Biomedical Research Centre (NIHR203312). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.


### 634 REFERENCES


635		
636	1.	Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in
637		Prostate Cancer Incidence and Mortality Rates. <i>Eur Urol.</i> 2020;77(1):38-52.
638	2.	Mucci LA, Hjelmborg JB, Harris JR, et al. Familial Risk and Heritability of Cancer
639		Among Twins in Nordic Countries. JAMA. 2016;315(1):68-76.
640	3.	Karunamuni RA, Huynh-Le MP, Fan CC, et al. Additional SNPs improve risk
641		stratification of a polygenic hazard score for prostate cancer. Prostate Cancer
642		Prostatic Dis. 2021;24(2):532-541.
643	4.	Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89.
644	5.	Adami H-O, Hunter DJ, Lagiou P, Mucci LA. Textbook of cancer epidemiology. Third
645		edition. ed. Oxford ; New York: Oxford University Press; 2018.
646	6.	Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer
647		metastasis and mortality at the time of diagnosis. J Natl Cancer Inst.
648		2009;101(12):878-887.
649	7.	Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of
650		cytomegalovirus: A systematic review and meta-analysis. <i>Rev Med Virol.</i>
651	•	2019;29(3):e2034.
652	8.	Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS. High prevalence of human
653		cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. <i>J Urol.</i>
654	0	2003;170(3):998-1002.
655 656	9.	Classon J, Stenudd M, Zamboni M, Alkass K, Eriksson C-J, Pedersen L, Schörling A, Thoss A, Bergh A, Wikström P, Adami H-O, Sørensen HT, Druid H, Frisén J.
657		Cytomegalovirus promotes proliferation and survival of prostate cancer cells and
658		constitutes a therapeutic target. <i>BioRxiv</i> 2023;10.1101/2023.10.01.560348
659	10.	Sutcliffe S, Till C, Gaydos CA, et al. Prospective study of cytomegalovirus serostatus
660	20.	and prostate cancer risk in the Prostate Cancer Prevention Trial. <i>Cancer Causes</i>
661		Control. 2012;23(9):1511-1518.
662	11.	Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to
663		cytomegalovirus, inflammation, all-cause and cardiovascular disease-related
664		mortality in the United States. PLoS One. 2011;6(2):e16103.
665	12.	Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ.
666		Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus
667		are associated with mortality in the population-based European prospective
668		investigation of Cancer-Norfolk cohort. Clin Infect Dis. 2013;56(10):1421-1427.
669	13.	Okedele OO, Nelson HH, Oyenuga ML, Thyagarajan B, Prizment A. Cytomegalovirus
670		and cancer-related mortality in the national health and nutritional examination
671		survey. Cancer Causes Control. 2020;31(6):541-547.
672	14.	Classon J, Zamboni M, Engblom C, et al. Prostate cancer disease recurrence after
673		radical prostatectomy is associated with HLA type and local cytomegalovirus
674	4-	immunity. <i>Mol Oncol.</i> 2022.
675	15.	Stanier P, Taylor DL, Kitchen AD, Wales N, Tryhorn Y, Tyms AS. Persistence of
676 677		cytomegalovirus in mononuclear cells in peripheral blood from blood donors. BMJ.
677		1989;299(6704):897-898.

678 679	16.	Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells.
680		J Gen Virol. 1991;72 ( Pt 9):2059-2064.
681	17.	Kraat YJ, Hendrix MG, Wijnen RM, et al. Detection of latent human cytomegalovirus
682		in organ tissue and the correlation with serological status. <i>Transpl Int.</i> 1992;5 Suppl
683		1:S613-616.
684	18.	Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human
685		cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis.
686		1995;171(4):1002-1006.
687	19.	Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human
688		cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol. 1996;77 (Pt
689		12):3099-3102.
690	20.	Hendrix RM, Wagenaar M, Slobbe RL, Bruggeman CA. Widespread presence of
691		cytomegalovirus DNA in tissues of healthy trauma victims. J Clin Pathol.
692		1997;50(1):59-63.
693	21.	Larsson S, Soderberg-Naucler C, Wang FZ, Moller E. Cytomegalovirus DNA can be
694		detected in peripheral blood mononuclear cells from all seropositive and most
695		seronegative healthy blood donors over time. <i>Transfusion</i> . 1998;38(3):271-278.
696	22.	Roback JD, Hillyer CD, Drew WL, et al. Multicenter evaluation of PCR methods for
697		detecting CMV DNA in blood donors. <i>Transfusion</i> . 2001;41(10):1249-1257.
698	23.	Loeth N, Assing K, Madsen HO, Vindelov L, Buus S, Stryhn A. Humoral and cellular
699		CMV responses in healthy donors; identification of a frequent population of CMV-
700		specific, CD4+ T cells in seronegative donors. <i>PLoS One.</i> 2012;7(2):e31420.
701	24.	Litjens NHR, Huang L, Dedeoglu B, Meijers RWJ, Kwekkeboom J, Betjes MGH.
702		Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney
703		Transplant Patients without Serum Anti-CMV Antibodies. Front Immunol.
704	25	2017;8:1137.
705	25.	Terlutter F, Caspell R, Nowacki TM, et al. Direct Detection of T- and B-Memory
706 707		Lymphocytes by ImmunoSpot(R) Assays Reveals HCMV Exposure that Serum Antibodies Fail to Identify. <i>Cells.</i> 2018;7(5).
707	26.	Ashokkumar C, Green M, Soltys K, et al. CD154-expressing CMV-specific T cells
708	20.	associate with freedom from DNAemia and may be protective in seronegative
710		recipients after liver or intestine transplantation. <i>Pediatr Transplant</i> .
711		2020;24(1):e13601.
712	27.	Jackson SE, Sedikides GX, Okecha G, Poole EL, Sinclair JH, Wills MR. Latent
713	27.	Cytomegalovirus (CMV) Infection Does Not Detrimentally Alter T Cell Responses in
714		the Healthy Old, But Increased Latent CMV Carriage Is Related to Expanded CMV-
715		Specific T Cells. Front Immunol. 2017;8:733.
716	28.	Parry HM, Zuo J, Frumento G, et al. Cytomegalovirus viral load within blood increases
717		markedly in healthy people over the age of 70 years. <i>Immun Ageing</i> . 2016;13:1.
718	29.	Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J
719		<i>Virol.</i> 1999;73(6):4806-4812.
720	30.	Xu GJ, Kula T, Xu Q, et al. Viral immunology. Comprehensive serological profiling of
721		human populations using a synthetic human virome. Science.
722		2015;348(6239):aaa0698.
723	31.	Pou C, Nkulikiyimfura D, Henckel E, et al. The repertoire of maternal anti-viral
724		antibodies in human newborns. Nat Med. 2019;25(4):591-596.


725 726 727	32.	Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. <i>Br J Cancer</i> . 1999;80 Suppl 1:95-103.
728	33.	Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Higher
729	55.	immunoglobulin G antibody levels against cytomegalovirus are associated with
730		incident ischemic heart disease in the population-based EPIC-Norfolk cohort. J Infect
731		Dis. 2012;206(12):1897-1903.
732	34.	Mentzer AJ, Brenner N, Allen N, et al. Identification of host-pathogen-disease
733	54.	relationships using a scalable multiplex serology platform in UK Biobank. <i>Nat</i>
734		Commun. 2022;13(1):1818.
734	35.	Phillimore P, Beattie A, Townsend P. Widening inequality of health in northern
736	55.	England, 1981-91. <i>BMJ</i> . 1994;308(6937):1125-1128.
737	36.	Samson LD, van den Berg SP, Engelfriet P, et al. Limited effect of duration of CMV
738	50.	infection on adaptive immunity and frailty: insights from a 27-year-long longitudinal
739		study. <i>Clin Transl Immunology</i> . 2020;9(10):e1193.
739	37.	Komatsu H, Sierro S, A VC, Klenerman P. Population analysis of antiviral T cell
740	57.	responses using MHC class I-peptide tetramers. <i>Clin Exp Immunol.</i> 2003;134(1):9-12.
742	38.	Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United
742	50.	States: the national health and nutrition examination surveys, 1988-2004. <i>Clin Infect</i>
743 744		<i>Dis.</i> 2010;50(11):1439-1447.
745	39.	Korodi Z, Wang X, Tedeschi R, Knekt P, Dillner J. No serological evidence of
746	39.	association between prostate cancer and infection with herpes simplex virus type 2
747		or human herpesvirus type 8: a nested case-control study. J Infect Dis.
748		2005;191(12):2008-2011.
749	40.	Sutcliffe S, Giovannucci E, Gaydos CA, et al. Plasma antibodies against Chlamydia
750	40.	trachomatis, human papillomavirus, and human herpesvirus type 8 in relation to
751		prostate cancer: a prospective study. <i>Cancer Epidemiol Biomarkers Prev.</i>
752		2007;16(8):1573-1580.
753	41.	Mahal BA, Berman RA, Taplin ME, Huang FW. Prostate Cancer-Specific Mortality
754	41.	Across Gleason Scores in Black vs Nonblack Men. JAMA. 2018;320(23):2479-2481.
755	42.	Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE. Cause-specific mortality
756	72.	following radical prostatectomy. <i>Prostate Cancer Prostatic Dis.</i> 2012;15(1):106-110.
757	43.	Banerjee S, Alwine JC, Wei Z, et al. Microbiome signatures in prostate cancer.
758	43.	Carcinogenesis. 2019;40(6):749-764.
759	44.	Hurst R, Meader E, Gihawi A, et al. Microbiomes of Urine and the Prostate Are Linked
760		to Human Prostate Cancer Risk Groups. <i>Eur Urol Oncol.</i> 2022.
761	45.	Pernigoni N, Zagato E, Calcinotto A, et al. Commensal bacteria promote endocrine
762	13.	resistance in prostate cancer through androgen biosynthesis. <i>Science</i> .
763		2021;374(6564):216-224.
764	46.	Moss P. 'From immunosenescence to immune modulation': a re-appraisal of the role
765		of cytomegalovirus as major regulator of human immune function. <i>Med Microbiol</i>
766		Immunol. 2019;208(3-4):271-280.
767		
768		







A) Quantification of percentage CMV-pp71 abundance in prostate areas with epithelial cells in prostate from post-mortem donors. Difference between CMV seronegative (IgG<sup>-</sup>; n=17) and CMV seropositive (IgG<sup>+</sup>; n=24) men was examined with un-paired two-tailed t-test. p<0.0001=\*\*\*\*. Bar graph shows mean±SD. B) Abundance of CMVpp71 (%) in prostates with high prostate CMV IgG VirScore ( $\geq 6$ ) compared to low CMV IgG VirScore (< 6), n=15, analyzed with un-paired two-tailed t-test. P<0.001=\*\*\*. Bar graph shows mean±SD. C) Abundance of CMV-pp71 (%) in tumors, determined with IHC, compared between CMV seronegative (IgG<sup>-</sup>; n=10) and CMV seropositive (IgG<sup>+</sup>; n=10) prostate cancer patients with Mann-Whitney test. Bar graph shows mean±SD. P<0.05=\*. Analysis underneath graph shows Fisher's exact test of fraction of samples with >90% cancer CMV abundance comparing CMV seropositive (2/10) and seronegative (8/10) patients. D) Receiver operator characteristic (ROC) curve for CMV-pp71 epithelial abundance (%) in CMV seropositive post-mortem donors in (A) (in red) compared to CMV seronegative post-mortem donors in (A) (in grey). AUC = Area under the curve. E) ROC curve for CMV-pp71 cancer abundance in CMV seropositive prostate cancer patients in (C) (in red) compared to CMV seronegative prostate cancer patients in (C) (in grey). AUC = Area under the curve.



# Figure 2: Flow charts of EPIC-Norfolk CMV and prostate cancer study

**A)** Study design of the EPIC-Norfolk cohort in which CMV serostatus (CMV IgG<sup>-</sup> vs CMV IgG<sup>+</sup>) and risk of prostate cancer (prostate cancer incidence) was examined. Patients with prevalent prostate cancer and those with less than two years follow up time from CMV serostatus determination to a documented prostate cancer diagnosis were excluded. **B)** Study design of the EPIC-Norfolk cohort in which CMV serostatus (CMV IgG<sup>-</sup> vs CMV IgG<sup>+</sup>) and risk of overall mortality and prostate cancer mortality was examined. All men in the cohort, excluding patients with prevalent prostate cancer and those with less than two years follow up time from CMV serostatus determination to death were analyzed. Patients with incident prostate cancer with more than two years follow up were examined in independent analyses. Green boxes indicate prostate cancer cases. Red boxes indicate mortality as endpoint in analyses.

25

	Hazard ratio (CI 95%)	p-value	
Model 1 (Un-adjusted)	1.17 (1.01-1.34)	0.035	n=7427, 778 events
Model 2 (age-adjusted)	0.99 (0.85-1.14)	0.848	n=7427, 778 events
Model 3 (fully adjusted)*	1.03 (0.89-1.19)	0.687	n=7324, 766 events

# Table 1: CMV seropositivity and prostate cancer incidence

\*Adjusted for Age, Townsend index, Diabetes Mellitus, Body Mass Index, Waist-Hip Ratio, Education level and Smoking. Cox proportional hazard models. CI: Confidence Interval.

Hazard ratio (CI 95%) p-value All-cause mortality in patients with prostate cancer Model 1 (Un-adjusted) 1.35(1.06-1.72)0.014 N=597, 288 events Model 2 (age-adjusted) 1.21 (0.95-1.54) 0.121 N=597, 288 events Model 3 (fully adjusted)\* 1.17 (0.92-1.50) 0.206 N=588, 281 events Prostate cancer mortality in patients with prostate cancer Model 1 (Un-adjusted) 2.47 (1.12-5.43) 0.024 N=597, 130 events N=597, 130 events Model 2 (age-adjusted) 2.32 (1.06-5.13) 0.036 Model 3 (fully adjusted)\* 2.26 (1.02-4.99) 0.044 N=588, 126 events All-cause mortality in all men Model 1 (Un-adjusted) 1.45 (1.34-1.56) < 0.001 N=7479, 3013 events N=7479, 3013 events Model 2 (age-adjusted) 1.11(1.03-1.20)0.006 Model 3 (fully adjusted)\* 1.10(1.02-1.18)0.019 N=7375, 2960 events Prostate cancer mortality in all men 1.61 (1.20-2.17) Model 1 (Un-adjusted) 0.001 N=7479, 199 events Model 2 (age-adjusted) N=7479, 199 events 1.24 (0.92-1.67) 0.155 Model 3 (fully adjusted)\* 1.24 (0.92-1.67) N=7375, 193 events 0.164

### Table 2: CMV seropositivity, prostate cancer mortality and all-cause mortality

Prostate cancer patients are defined as incident cases, i.e. that their diagnoses are registered after CMV serostatus examination. CMV seropositive patients are compared to CMV seronegative patients. \*Adjusted for Age, Townsend index, Diabetes Mellitus, Body Mass Index, Waist-Hip Ratio, Education level and Smoking. Cox proportional hazard models. CI: Confidence Interval.